Detection of polyethylene glycol thyrotropin (TSH) precipitable percentage (macro-TSH) in patients with a history of thyroid cancer

Massimo Giusti, Lucia Conte, Anna Maria Repetto, Stefano Gay, Paola Marroni, Miranda Mittica, Michele Mussap

Research output: Contribution to journalArticle

Abstract

Background: Owing to its large molecular size, polyethylene glycol (PEG)-precipitable thyrotropin (TSH) can accumulate in the circulation, elevating TSH levels. PEG-precipitable TSH can be used to detect macro-TSH (mTSH) in serum. Our aim was to evaluate the prevalence of mTSH in patients who had undergone thyroidectomy for thyroid cancer. Methods: Seventy-three thyroid cancer patients and 24 control subjects on levothyroxine (LT4) TSH-suppressive or replacement therapy were evaluated. Screening for mTSH was performed by adding PEG to serum in order to precipitate ?-globulin. A percentage of PEG-precipitable TSH =80% was considered suggestive of mTSH. Results: No correlation between free-T4 (fT4) and TSH levels was found. PEG-precipitable TSH was 39.3%±1.9% in thyroid cancer patients and 44.1%±3.9% in controls. Macro-TSH was deemed to be present in one thyroid cancer patient and in two control subjects. Only in the thyroid cancer group was PEG-precipitable TSH found to be negatively correlated with fT4 concentration. No correlation was found between PEG-precipitable TSH and other clinical conditions in any patients. Conclusion: The presence of mTSH seems to be a rare phenomenon in thyroid cancer. In some patients with low PEG-precipitable TSH, a reduction in LT4 dosage could be suggested. LT4 dosage adjusted to body weight is the main factor in maintaining TSH in a semi-suppressed or normal range. Evaluation of mTSH could be necessary in patients in whom a balance is required between adequate TSH suppression and the avoidance of unnecessary exogenous hyperthyroxinemia.

Original languageEnglish
Pages (from-to)460-465
Number of pages6
JournalEndocrinology and Metabolism
Volume32
Issue number4
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Thyrotropin
Thyroid Neoplasms
Hyperthyroxinemia
Thyroidectomy
Globulins
Serum
Thyroxine
Reference Values
Body Weight

Keywords

  • Levothyroxine-posology
  • Macro-thyrotropin
  • Polyethylene glycol-precipitable thyrotropin
  • Thyroid neoplasms
  • Thyrotropin

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Detection of polyethylene glycol thyrotropin (TSH) precipitable percentage (macro-TSH) in patients with a history of thyroid cancer. / Giusti, Massimo; Conte, Lucia; Repetto, Anna Maria; Gay, Stefano; Marroni, Paola; Mittica, Miranda; Mussap, Michele.

In: Endocrinology and Metabolism, Vol. 32, No. 4, 01.12.2017, p. 460-465.

Research output: Contribution to journalArticle

Giusti, Massimo ; Conte, Lucia ; Repetto, Anna Maria ; Gay, Stefano ; Marroni, Paola ; Mittica, Miranda ; Mussap, Michele. / Detection of polyethylene glycol thyrotropin (TSH) precipitable percentage (macro-TSH) in patients with a history of thyroid cancer. In: Endocrinology and Metabolism. 2017 ; Vol. 32, No. 4. pp. 460-465.
@article{3ace8e33477743ac8449c172eb0bad11,
title = "Detection of polyethylene glycol thyrotropin (TSH) precipitable percentage (macro-TSH) in patients with a history of thyroid cancer",
abstract = "Background: Owing to its large molecular size, polyethylene glycol (PEG)-precipitable thyrotropin (TSH) can accumulate in the circulation, elevating TSH levels. PEG-precipitable TSH can be used to detect macro-TSH (mTSH) in serum. Our aim was to evaluate the prevalence of mTSH in patients who had undergone thyroidectomy for thyroid cancer. Methods: Seventy-three thyroid cancer patients and 24 control subjects on levothyroxine (LT4) TSH-suppressive or replacement therapy were evaluated. Screening for mTSH was performed by adding PEG to serum in order to precipitate ?-globulin. A percentage of PEG-precipitable TSH =80{\%} was considered suggestive of mTSH. Results: No correlation between free-T4 (fT4) and TSH levels was found. PEG-precipitable TSH was 39.3{\%}±1.9{\%} in thyroid cancer patients and 44.1{\%}±3.9{\%} in controls. Macro-TSH was deemed to be present in one thyroid cancer patient and in two control subjects. Only in the thyroid cancer group was PEG-precipitable TSH found to be negatively correlated with fT4 concentration. No correlation was found between PEG-precipitable TSH and other clinical conditions in any patients. Conclusion: The presence of mTSH seems to be a rare phenomenon in thyroid cancer. In some patients with low PEG-precipitable TSH, a reduction in LT4 dosage could be suggested. LT4 dosage adjusted to body weight is the main factor in maintaining TSH in a semi-suppressed or normal range. Evaluation of mTSH could be necessary in patients in whom a balance is required between adequate TSH suppression and the avoidance of unnecessary exogenous hyperthyroxinemia.",
keywords = "Levothyroxine-posology, Macro-thyrotropin, Polyethylene glycol-precipitable thyrotropin, Thyroid neoplasms, Thyrotropin",
author = "Massimo Giusti and Lucia Conte and Repetto, {Anna Maria} and Stefano Gay and Paola Marroni and Miranda Mittica and Michele Mussap",
year = "2017",
month = "12",
day = "1",
doi = "10.3803/EnM.2017.32.4.460",
language = "English",
volume = "32",
pages = "460--465",
journal = "Endocrinology and Metabolism",
issn = "2093-596X",
publisher = "Korean Endocrine Society",
number = "4",

}

TY - JOUR

T1 - Detection of polyethylene glycol thyrotropin (TSH) precipitable percentage (macro-TSH) in patients with a history of thyroid cancer

AU - Giusti, Massimo

AU - Conte, Lucia

AU - Repetto, Anna Maria

AU - Gay, Stefano

AU - Marroni, Paola

AU - Mittica, Miranda

AU - Mussap, Michele

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Background: Owing to its large molecular size, polyethylene glycol (PEG)-precipitable thyrotropin (TSH) can accumulate in the circulation, elevating TSH levels. PEG-precipitable TSH can be used to detect macro-TSH (mTSH) in serum. Our aim was to evaluate the prevalence of mTSH in patients who had undergone thyroidectomy for thyroid cancer. Methods: Seventy-three thyroid cancer patients and 24 control subjects on levothyroxine (LT4) TSH-suppressive or replacement therapy were evaluated. Screening for mTSH was performed by adding PEG to serum in order to precipitate ?-globulin. A percentage of PEG-precipitable TSH =80% was considered suggestive of mTSH. Results: No correlation between free-T4 (fT4) and TSH levels was found. PEG-precipitable TSH was 39.3%±1.9% in thyroid cancer patients and 44.1%±3.9% in controls. Macro-TSH was deemed to be present in one thyroid cancer patient and in two control subjects. Only in the thyroid cancer group was PEG-precipitable TSH found to be negatively correlated with fT4 concentration. No correlation was found between PEG-precipitable TSH and other clinical conditions in any patients. Conclusion: The presence of mTSH seems to be a rare phenomenon in thyroid cancer. In some patients with low PEG-precipitable TSH, a reduction in LT4 dosage could be suggested. LT4 dosage adjusted to body weight is the main factor in maintaining TSH in a semi-suppressed or normal range. Evaluation of mTSH could be necessary in patients in whom a balance is required between adequate TSH suppression and the avoidance of unnecessary exogenous hyperthyroxinemia.

AB - Background: Owing to its large molecular size, polyethylene glycol (PEG)-precipitable thyrotropin (TSH) can accumulate in the circulation, elevating TSH levels. PEG-precipitable TSH can be used to detect macro-TSH (mTSH) in serum. Our aim was to evaluate the prevalence of mTSH in patients who had undergone thyroidectomy for thyroid cancer. Methods: Seventy-three thyroid cancer patients and 24 control subjects on levothyroxine (LT4) TSH-suppressive or replacement therapy were evaluated. Screening for mTSH was performed by adding PEG to serum in order to precipitate ?-globulin. A percentage of PEG-precipitable TSH =80% was considered suggestive of mTSH. Results: No correlation between free-T4 (fT4) and TSH levels was found. PEG-precipitable TSH was 39.3%±1.9% in thyroid cancer patients and 44.1%±3.9% in controls. Macro-TSH was deemed to be present in one thyroid cancer patient and in two control subjects. Only in the thyroid cancer group was PEG-precipitable TSH found to be negatively correlated with fT4 concentration. No correlation was found between PEG-precipitable TSH and other clinical conditions in any patients. Conclusion: The presence of mTSH seems to be a rare phenomenon in thyroid cancer. In some patients with low PEG-precipitable TSH, a reduction in LT4 dosage could be suggested. LT4 dosage adjusted to body weight is the main factor in maintaining TSH in a semi-suppressed or normal range. Evaluation of mTSH could be necessary in patients in whom a balance is required between adequate TSH suppression and the avoidance of unnecessary exogenous hyperthyroxinemia.

KW - Levothyroxine-posology

KW - Macro-thyrotropin

KW - Polyethylene glycol-precipitable thyrotropin

KW - Thyroid neoplasms

KW - Thyrotropin

UR - http://www.scopus.com/inward/record.url?scp=85038881353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038881353&partnerID=8YFLogxK

U2 - 10.3803/EnM.2017.32.4.460

DO - 10.3803/EnM.2017.32.4.460

M3 - Article

AN - SCOPUS:85038881353

VL - 32

SP - 460

EP - 465

JO - Endocrinology and Metabolism

JF - Endocrinology and Metabolism

SN - 2093-596X

IS - 4

ER -